| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 04/18/2002 | WO2002030359A2 Methods for enhancing lysing of coagulated blood with apolipoprotein e2 phenotype |
| 04/18/2002 | WO2002030355A2 Composition and method of alleviating adverse side effects and/or enhancing efficacy of agents that inhibit aromatase |
| 04/18/2002 | WO2002030351A2 Improvement of graft acceptance through manipulation of thymic regeneration |
| 04/18/2002 | WO2002030320A2 Stimulation of thymus for vaccination development |
| 04/18/2002 | WO2002030259A2 Disease prevention by reactivation of the thymus |
| 04/18/2002 | WO2002030257A2 Normalization of defective t cell responsiveness through manipulation of thymic regeneration |
| 04/18/2002 | WO2002030256A2 Diagnostic indicator of thymic function |
| 04/18/2002 | WO2002030184A1 Modulating cytokine or hormone signalling in an animal comprising up-regulating the expression of socs sequence in the animal |
| 04/18/2002 | WO2002030183A1 Genetic control of sex ratio in animal populations |
| 04/18/2002 | WO2002017968A3 Sensitization of cancer cells to immunoconjugate-induced cell death by transfection with il-13 receptor alpha chain-2 |
| 04/18/2002 | WO2002014499A9 Claudin polypeptides |
| 04/18/2002 | WO2002013760A3 Methods and compositions for the repair and/or regeneration of damaged myocardium |
| 04/18/2002 | WO2002011742A3 Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders |
| 04/18/2002 | WO2002008272A3 High affinity soluble interleukin-18 receptor |
| 04/18/2002 | WO2002006478A3 Extracellular matrix protein |
| 04/18/2002 | WO2002006301A3 Peptides with antioxidant and antimicrobial properties |
| 04/18/2002 | WO2002003921A3 Bax fragment induced tumor cell death |
| 04/18/2002 | WO2002000248A3 Use of urokinase inhibitors for the treatment and/or prevention of pulmonary hypertension and/or cardiac remodelling |
| 04/18/2002 | WO2001093806A3 HMG CoA REDUCTASE INHIBITORS FOR PROMOTING ANGIOGENESIS |
| 04/18/2002 | WO2001087265A3 Pharmaceutical form of administration for peptides, methods for its production and use |
| 04/18/2002 | WO2001085766A3 Novel eosinophil cationic proteins used in the treatment of asthmatic and allergic disorders |
| 04/18/2002 | WO2001085136A3 Phospholipid-based powders for drug delivery |
| 04/18/2002 | WO2001083707A3 Chondrocyte cultures and anti-angiogenic fractions therefrom |
| 04/18/2002 | WO2001082952A3 USE OF α-MSH AND EPO FOR PREVENTING OR TREATING ISCHEMIC CONDITIONS |
| 04/18/2002 | WO2001081559A3 26335, a novel human serine/threonine dehydratase and uses thereof |
| 04/18/2002 | WO2001078682A3 Sustained release drug compositions |
| 04/18/2002 | WO2001077177A8 Gpcr-proteins and nucleic acids encoding same |
| 04/18/2002 | WO2001075054A3 A novel polypeptide, microglobulin transcription human regulation factor 30 and the polynucleotide encoding the polypeptide |
| 04/18/2002 | WO2001075051A3 A novel polypeptide, a human stroma antigen 3 protein 17 and the polynucleotide encoding the polypeptide |
| 04/18/2002 | WO2001072955A3 Regulation of human nedd1-related protein |
| 04/18/2002 | WO2001072777A3 Human transcription factors |
| 04/18/2002 | WO2001070985A3 Bi-functional cancer treatment agents |
| 04/18/2002 | WO2001070954A3 Regulation of human nerve growth factor-elated g protein-coupled receptor |
| 04/18/2002 | WO2001070288A3 Thermoreversible polymers for delivery and retention of osteoinductive proteins |
| 04/18/2002 | WO2001070247A3 Salmonella vaccine materials and methods |
| 04/18/2002 | WO2001066765A3 26583, a serine/threonine phosphatase and uses thereof |
| 04/18/2002 | WO2001066764A3 16835, a human phospholipase c and uses thereof |
| 04/18/2002 | WO2001066595A3 Human fgf-23 gene and gene expression products |
| 04/18/2002 | WO2001064876A3 Human schizophrenia gene |
| 04/18/2002 | WO2001064856A3 Regulators of type-1 tumor necrosis factor receptor and other cytokine receptor shedding |
| 04/18/2002 | WO2001064752A3 Antibody inhibiting the binding between gp120 and dc-sign and screening methods |
| 04/18/2002 | WO2001064724A3 Maurocalcine, analogues thereof and their therapeutical uses |
| 04/18/2002 | WO2001062918A3 Secretory polypeptides and corresponding polynucleotides |
| 04/18/2002 | WO2001062893A3 Compounds and methods for diagnosis and immunotherapy of tuberculosis |
| 04/18/2002 | WO2001061007A9 Fibroblast growth factor-23 molecules and uses thereof |
| 04/18/2002 | WO2001060400A3 Use of inhibitors of caspase-3 or caspase-activated desoxyribonuclease (cad) for treating cardiac disease |
| 04/18/2002 | WO2001060377A3 Methods for treatment of lysosomal storage diseases using biphosphonates |
| 04/18/2002 | WO2001060152A3 Transgenic non-human ucp2 knockout mammal |
| 04/18/2002 | WO2001059087A3 Compositions for transfecting nucleic acids and their use |
| 04/18/2002 | WO2001058916A3 Antibodies to ccr5 |
| 04/18/2002 | WO2001055214A3 Asthma-associated gene |
| 04/18/2002 | WO2001053330A3 High purity lipopeptides, lipopeptide micelles, processes for preparing same and pharmaceutical compositions containing them |
| 04/18/2002 | WO2001051632A3 Odorant receptor polypeptides and nucleic acids encoding same |
| 04/18/2002 | WO2001051520A3 Nogo receptor-mediated blockade of axonal growth |
| 04/18/2002 | WO2001051080A3 Methods and compositions for obtaining disease protection for animals |
| 04/18/2002 | WO2001049743A3 Methods of modulation of the immune system |
| 04/18/2002 | WO2001046262A3 Olfactory receptor genes and pseudogenes in primates and mouse |
| 04/18/2002 | WO2001040271A3 Cancer associated antigens and uses therefor |
| 04/18/2002 | WO2001027277A3 Proteins and polynucleotides encoded thereby |
| 04/18/2002 | WO2001025437A3 Growth factor polypeptides and nucleic acids encoding same |
| 04/18/2002 | WO2001024832A3 Pharmaceutical composition for treating and preventing human tumors, which express the tumor antigen mucin and/or the carcinoembryonic antigen (cea), and the use thereof |
| 04/18/2002 | WO2000075184A9 Modulation of protein levels using the scf complex |
| 04/18/2002 | WO2000073482A9 Use of recombinant gene delivery vectors for treating or preventing lysosomal storage disorders |
| 04/18/2002 | WO2000073467A9 Snf2 related cbp activator protein (srcap) |
| 04/18/2002 | WO2000072856A9 Fibrin sealants providing less inflammatory response and methods using same |
| 04/18/2002 | WO2000070341A9 Methods, pharmaceutical formulations and kits for identification of subjects at risk for cancer |
| 04/18/2002 | WO2000069454A9 Suppression of endogenous igfbp-2 to inhibit cancer |
| 04/18/2002 | WO2000068387A9 Nucleic acids and proteins with interferon-beta activity |
| 04/18/2002 | WO2000068385A9 Novel nucleic acids and proteins with growth hormone activity |
| 04/18/2002 | WO2000067793A9 Death domain containing receptor 4 |
| 04/18/2002 | WO2000061177A9 Composition based on oppositely-charged polypeptides |
| 04/18/2002 | WO2000055192A3 Hemocyanin and nucleic acid sequence coding for the same |
| 04/18/2002 | US20020046413 Transgenic mice containing BMP gene disruptions |
| 04/18/2002 | US20020045747 Treating Alzheimer's disease both prophylactically and therapeutically |
| 04/18/2002 | US20020045742 Dna encoding a gaba b r2 polypeptide and uses thereof |
| 04/18/2002 | US20020045741 Novel haemopoietin receptor and genetic sequence encoding same |
| 04/18/2002 | US20020045735 Isolating glycoproteins from solution; obtain sample, homogenize, incubate with acetic acid, recover preferential glycoproteins |
| 04/18/2002 | US20020045734 Geneticaly engineered polypeptide for use drug delivery tools |
| 04/18/2002 | US20020045636 Administering a drug composition comprising an opioidergic agent (e.g. an opiate antagonist, an opiate having mu-agonist activity, or a combination) and an insulin secretagogue |
| 04/18/2002 | US20020045601 Ophthalmic compositions |
| 04/18/2002 | US20020045600 Topical skin treatment for sea lice, insect bites and skin irritation |
| 04/18/2002 | US20020045593 Use of the interferon receptor 2c polypeptide chain to enhance the anti-growth effects of type I interferons |
| 04/18/2002 | US20020045591 For gene therapy including polynucleotide sequences encoding peptides including beta-catenin binding domains such as cadherins, for treating cancers with abnormally high levels of beta-catenin |
| 04/18/2002 | US20020045590 Inhibition of interaction of PSD93 and PSD95 with nNOS and NMDA receptors |
| 04/18/2002 | US20020045589 Hirulogs are a group of synthetic thrombin-specific inhibitors which conserve the major active sites of hirudin; treatment of vascular restenosis |
| 04/18/2002 | US20020045588 Telomerase Reverse Transcriptase (TERT); treatment of cancer; modulating apoptosis |
| 04/18/2002 | US20020045583 Use as hypolipidemic |
| 04/18/2002 | US20020045579 Modulation of inflammation related to columnar epithelia |
| 04/18/2002 | US20020045578 Tumor necrosis factor receptor 1 death domain (TNFR-1 DD); using structure to identify inhibitors to TNFR-1 DD; computer analysis based drug screening |
| 04/18/2002 | US20020045577 Human schizophrenia gene |
| 04/18/2002 | US20020045576 Novel neurotrophic factor |
| 04/18/2002 | US20020045575 Treating inflammatory, autoimmune diseases, including graft-versus-host disease and enhancement of graft/tissue survival following transplant |
| 04/18/2002 | US20020045574 Vancomycin analogs having improved activity against bacterial infection |
| 04/18/2002 | US20020045572 Method of treating the syndrome of type 2 diabetes in humans |
| 04/18/2002 | US20020045571 Reduced-viscosity concentrated protein formulations |
| 04/18/2002 | US20020045569 Compositions for treating diabetic retinopathy and methods of using same |
| 04/18/2002 | US20020045568 Use of mp52 0r mp121 for treating and preventing diseases of the nervous system |
| 04/18/2002 | US20020045567 Synthetic proteins for in vivo drug delivery and tissue augmentation |
| 04/18/2002 | US20020045261 Genetically engineered cells for use in the treatment of tumors; antitumor agents |
| 04/18/2002 | US20020045248 Intracellular inhibitors of gq protein signaling |